Nektar Therapeutics Inc. continued its string of partnerships by hooking Eli Lilly and Co. as a collaborator to co-develop NKTR-358, a candidate advanced from inception to the clinic in a mere 15 months. Terms call for Nektar, of San Francisco, to receive $150 million up front with the potential for up to $250 million in additional development and regulatory milestones.